AHR and prostate cancer: Although TDO2 is highly expressed in the liver, which may hinder the development of TDO2 small molecule inhibitors, our study may advocate targeting TDO2-Kyn-AhR signalling as a new adjuvant therapy for androgen-sensitive prostate cancer patients treated with ADT.